Recently, PI and IMiD combination treatment was shown to work synergistically via calpain-dependent IKZF1 cleavage [69] and stabilization of CRBN levels [70], suggesting that PI plus POM treatment might be a promising alternative for LEN-refractory myeloma. The gene discussed is IKZF1; the disease is plasma cell myeloma.